<DOC>
	<DOC>NCT01430442</DOC>
	<brief_summary>The purpose of this study is the exploration of a wide range of BMS-927711 doses that will reveal at least one dose that is safe and clinically superior to placebo in the treatment of acute migraine.</brief_summary>
	<brief_title>Dose Ranging Study of a Drug for the Treatment of Acute Migraine</brief_title>
	<detailed_description>Intervention Model: Parallel Versus Comparator + Placebo</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Patient with at least 1 year history of migraines (with or without aura) including the following; Migraine attacks more than 1 year with age onset prior to 50 years of age; Migraine attacks, on average, last about 4 72 hours if untreated; No more than 8 attacks of moderate to severe intensity per month within last 3 months; Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of severe to moderate intensity in each of the last 3 months; Less than 15 days of headache (migraine or non migraine) per month in each of 3 months prior to screening; Male and female ≥ 18 years and ≤ age 65 No clinically significant abnormality identified on the medical or laboratory evaluation Patient has a history of basilar migraine or hemiplegic migraine Patient does not receive migraine relief from triptan migraine treatment Medications that may alter the pH of the stomach (acid reducing agents), such as H2 antagonists, Proton Pump inhibitors (PPI), antacids History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months History of nonnarcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>